The UK RECOVERY trial investigators recently disclosed that Regeneron’s REGEN-COV, a pair of monoclonal antibodies, actually reduced the risk of death by 20% in patients hospitalized with COVID-19 who failed to sustain their own immune response. According to the company’s press release, this monoclonal antibody cocktail represents the first antibody treatment that improved survival in patients hospitalized with COVID-19. The company will not only share this data with regulatory authorities immediately but will also seek to expand its U.S. EUA to include appropriate hospitalized patients.
TrialSite provides a brief summary breakdown of this most recent information generated by the UK RECOVERY trial. Note that this platform was developed initially using a Sentinel agreement with the U.S. Food and Drug Administration (FDA) during the early days of the pandemic. TrialSite is pleased to report that this company has been one of the more transparent ones meaning when questions were submitted to company spokespersons they were quick to turn around and send answers.
What is the UK RECOVERY trial?
The RECOVERY trial (Randomized Evaluation of COVid-19 thERapY) was conducted by the ...
Note: If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).